checkAd
    Startseite > Aktien > BeyondSpring > Nachrichten
    BeyondSpring Aktie
    2,6300
     
    USD
    -2,95 %
    -0,0800 USD
    Letzter Kurs 02:00:00 Nasdaq
    2,6300
     
    USD
    1.100 STK
    Geldkurs 31.05.24
    2,6500
     
    USD
    600 STK
    Briefkurs 31.05.24
    ISIN: KYG108301006 · WKN: A2DNMQ · SYM: BYSI · Kaiman-Inseln

    Neueste Nachrichten

    BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
    16.05.24 · globenewswire · BeyondSpring
    BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
    03.05.24 · globenewswire · BeyondSpring
    BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results
    29.04.24 · globenewswire · BeyondSpring
    BeyondSpring Files 2023 Annual Report on Form 20-F
    29.04.24 · globenewswire · BeyondSpring
    BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
    25.03.24 · globenewswire · BeyondSpring
    BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements
    26.02.24 · globenewswire · BeyondSpring
    BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K
    10.01.24 · globenewswire · BeyondSpring
    BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
    18.12.23 · globenewswire · BeyondSpring
    BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitor
    07.11.23 · globenewswire · BeyondSpring
    BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere Models
    31.10.23 · globenewswire · BeyondSpring
    BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement
    30.10.23 · globenewswire · BeyondSpring
    SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium
    26.10.23 · globenewswire · BeyondSpring